MAP3K5 and metabolic dysfunction-associated steatohepatitis: In this study, we showed that selonsertib, a selective inhibitor of ASK1 that is currently in a phase III clinical trial on NASH [22], could effectively protect against LPS/GalN-induced ALF by inhibiting the activation of the hepatic ASK1–JNK–DRP1 pathway and alleviating mitochondrial damage in macrophages (Fig. 6).